<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500421</url>
  </required_header>
  <id_info>
    <org_study_id>H-D-2008-105</org_study_id>
    <nct_id>NCT01500421</nct_id>
  </id_info>
  <brief_title>Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)</brief_title>
  <official_title>The Øresund Copenhagen-Malmø Acute Stroke Cooling Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malmö University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safty and feasibility of therapeutic hypothermia in
      acute stroke patients. Soon after arrival in the stroke unit patients are randomized to
      either hypothermia in the intensive care unit (ICU) or standard treatment in the stroke ward.

      Patients randomized to therapeutic hypothermia are analgo-sedated and cooled to at
      temperature of 33 degrees for a period of 24 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic stroke remains a diagnosis with limited treatment opportunities and a treatment with
      the ability to target patients outside the normal treatment window is wanted.

      Therapeutic hypothermia (TH) treatment has long been recognised as a treatment of patients
      with global ischemia following caridac arrest.

      This trial is designed to address the safty and feasibility of TH in acute stroke patients.

      Patients arriving in our stroke ward are observed for 3 hours. Only non-remitting patients
      are allowed into the trial.

      Patients are randomized to either therapeutic hypothermia with endovascular catheter +
      nasopharyngeal induction or endovascular catheter alone in the intensive care unit (ICU) (in
      Copenhagen, Denmark) or intravenous cold saline infusion followed by surface cooling (in
      Malmø, Sweden)versus standard treatment in a stoke unit.

      Patients brought to the ICU are sedated and mechanically ventilated.

      Therapeutic hypothermia is induced with a endovascular catether and a nasopharyngeal
      catheter. Body temperature is lowered to 33 degrees and sustained for a period of 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and safety</measure>
    <time_frame>3 month</time_frame>
    <description>Feasibility and safety defined as mortality and morbidity 3 months after ictus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>3 months</time_frame>
    <description>mRS score after 7 days and 3 months</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>TH - Endovacular alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TH - Endovascular + nasopharyngeal induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are treated with standard care in the stroke ward.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TH - Surface Cooling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TH - Endovascular alone (Alsius®, Zoll, USA)</intervention_name>
    <description>Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).</description>
    <arm_group_label>TH - Endovacular alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)</intervention_name>
    <description>Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.</description>
    <arm_group_label>TH - Endovascular + nasopharyngeal induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)</intervention_name>
    <description>Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling</description>
    <arm_group_label>TH - Surface Cooling</arm_group_label>
    <other_name>Arctic Sun, Medivance, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  National Institute of Health Stroke Scale (NIHSS) score on admission between 5 and 18

          -  Inclusion within 24 hours after stroke onset

          -  Diagnosis of ischemic stroke verified by MRI, CT or CTP adjudicated by including
             physician

          -  Informed consent from patient or proxy

        Exclusion Criteria:

          -  Modified ranking scale (mRS)&gt;2 indicating significant disability before onset of
             stroke

          -  MRI or CT evidence for massive ischemic damage (&gt;50% Middle cerebral artery (MCA)
             territory)

          -  Severe concomitant diseases such as heart failure, chronic obstructive lung disease or
             known cancer

          -  Presently on anticoagulation treatment

          -  No informed consent from patient or proxy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>De Georgia MA, Krieger DW, Abou-Chebl A, Devlin TG, Jauss M, Davis SM, Koroshetz WJ, Rordorf G, Warach S. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology. 2004 Jul 27;63(2):312-7.</citation>
    <PMID>15277626</PMID>
  </reference>
  <reference>
    <citation>Hamann GF, Burggraf D, Martens HK, Liebetrau M, Jäger G, Wunderlich N, DeGeorgia M, Krieger DW. Mild to moderate hypothermia prevents microvascular basal lamina antigen loss in experimental focal cerebral ischemia. Stroke. 2004 Mar;35(3):764-9. Epub 2004 Feb 19.</citation>
    <PMID>14976330</PMID>
  </reference>
  <reference>
    <citation>Krieger DW, De Georgia MA, Abou-Chebl A, Andrefsky JC, Sila CA, Katzan IL, Mayberg MR, Furlan AJ. Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced hypothermia in acute ischemic stroke. Stroke. 2001 Aug;32(8):1847-54.</citation>
    <PMID>11486115</PMID>
  </reference>
  <reference>
    <citation>Lyden PD, Allgren RL, Ng K, Akins P, Meyer B, Al-Sanani F, Lutsep H, Dobak J, Matsubara BS, Zivin J. Intravascular Cooling in the Treatment of Stroke (ICTuS): early clinical experience. J Stroke Cerebrovasc Dis. 2005 May-Jun;14(3):107-14.</citation>
    <PMID>17904009</PMID>
  </reference>
  <reference>
    <citation>Milhaud D, Thouvenot E, Heroum C, Escuret E. Prolonged moderate hypothermia in massive hemispheric infarction: clinical experience. J Neurosurg Anesthesiol. 2005 Jan;17(1):49-53.</citation>
    <PMID>15632543</PMID>
  </reference>
  <reference>
    <citation>Schwab S, Georgiadis D, Berrouschot J, Schellinger PD, Graffagnino C, Mayer SA. Feasibility and safety of moderate hypothermia after massive hemispheric infarction. Stroke. 2001 Sep;32(9):2033-5.</citation>
    <PMID>11546893</PMID>
  </reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2011</study_first_posted>
  <last_update_submitted>December 27, 2011</last_update_submitted>
  <last_update_submitted_qc>December 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Derk W. Krieger MD, Ph.D</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypothermia, Induced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

